Clinical Trial: Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada

U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07370766) titled 'Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada' on Jan. 12.

Brief Summary: This is a multi-centre, non-interventional, open-label, prospective observational study that will be conducted across Canada over 52-week duration. Approximately 80 patients who are initiating tildrakizumab as part of their routine care through the ILUMYA SUPPORT(R) Program and meet the study's eligibility criteria will be enrolled. Specifically, the study will enroll patients with Fitzpatrick scale skin types III and above.

The real-world impact, safety and effectiveness of tildrakizumab on patie...